In the pharmaceutical industry, Amlodipine is a dihydropyridine Calcium Channel Blocker (CCB). As a pharmacist and manufacturer, I classify this as a “Low-Risk” medication for breastfeeding.
Clinical data indicates that Amlodipine passes into breast milk in very small amounts, which are generally considered insufficient to affect the nursing infant. However, at your WHO-GMP facility in Mumbai, we maintain a cautious stance by recommending clinical monitoring for any infant whose mother is on chronic therapy.
Safety Profile & Pharmacokinetics
| Parameter | Value / Status | Clinical Significance |
| Relative Infant Dose (RID) | < 4.2% | Significantly below the 10% safety threshold used by pediatricians. |
| Milk-to-Plasma Ratio | ~0.15 | Indicates very low penetration of the drug into the breast milk. |
| Protein Binding | 93% – 98% | High protein binding limits the amount of “free” drug available to enter the milk. |
| Infant Safety | Generally Safe | No adverse effects have been reported in infants exposed via breast milk. |
Mechanism: Selective Transport & Bioavailability
The safety of Amlodipine during breastfeeding is rooted in its molecular behavior.
-
Molecular Size & Ionization: Amlodipine molecules are relatively large and highly protein-bound in the mother’s blood. This makes it difficult for them to cross the biological membranes of the mammary glands.
-
Low Concentration: Studies have shown that the median concentration in breast milk is approximately $11.5\text{ mcg/L}$. For a 5kg infant, this represents an extremely negligible dose.
-
Infant Monitoring: While safe, as a pharmacist, you should advise B2B clients to instruct patients to monitor the infant for signs of low blood pressure, such as unusual lethargy or poor feeding.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai, here is how to position Amlodipine for your digital platforms:
-
Marketing Accuracy: When listing Amlodipine 2.5mg, 5mg, or 10mg tablets on your digital platforms, the “Lactation” section should reflect that it is a preferred CCB for breastfeeding mothers, alongside Nifedipine. This evidence-based positioning builds high trust with international medical distributors.
-
Stability & Packaging: Amlodipine is highly sensitive to light (photolabile). We utilize Alu-Alu blister packaging to ensure a 36-month shelf life. This is a critical selling point for export to Zone IVb tropical climates where light and humidity are high.
-
Dossier Readiness: Since Amlodipine is a staple in maternal health clinics for postpartum hypertension, we maintain full CTD/eCTD Dossiers to help your firm bid for national health and maternal-care tenders.
-
Bioequivalence: Highlight that your Amlodipine achieves bioequivalence with the innovator (Norvasc), ensuring international-grade safety and efficacy for both the mother and the infant.